ABSTRACT
Fusicoccin is the best-studied member of a class of diterpenes sharing a 5-8-5 ring structure, called fusicoccanes. Fusicoccin was and still is a 'tool in plant physiology', targeting the main engine of plasma membrane transport, the P-type H(+)-ATPase, assisted by members of the 14-3-3 family. The key position of 14-3-3 proteins in cell biology, combined with a broader specificity of other fusicoccanes as shown by crystallography studies, make fusicoccanes a versatile tool in plant and animal biology. In this review, we examine recent evidence that fusicoccanes act on animal cells, describe the discovery of the fungal biosynthetic pathway and emphasize that lower (liverworts) and higher plants produce fusicoccanes with intriguing biological activities.
Subject(s)
Diterpenes/metabolism , Glycosides/metabolism , Animals , Binding Sites , Biosynthetic Pathways , Conserved Sequence , Diterpenes/chemistry , Diterpenes/history , Glycosides/chemistry , Glycosides/history , History, 20th Century , Plant Proteins/metabolismABSTRACT
In 1951, the first reference to the antibacterial substance pleuromutilin was made in a paper published in the Proceedings of the National Academy of Sciences. Researchers had identified several species of the mold genus Pleurotus that inhibited the growth of Staphylococcus aureus. The elucidation of the structure in 1962 led to the initiation of a development program at Sandoz, which was followed by the approval of tiamulin in 1979 for use in veterinary medicine. Although in 2007 retapamulin became the first pleuromutilin approved for topical use in humans, it was not until 2011, exactly 60 years after the first mention of the class, that a pleuromutilin antibiotic, BC-3781, could be tested successfully in a clinical phase II trial for systemic use in patients. This review will discuss key aspects of this antibacterial class and provide some insight into the question of why it took half a century to develop a systemic pleuromutilin for human use.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/history , Bacterial Infections/drug therapy , Bacterial Infections/history , Diterpenes/chemistry , Diterpenes/history , Diterpenes/therapeutic use , Drug Discovery/history , Drug Resistance, Bacterial , History, 20th Century , History, 21st Century , Humans , Polycyclic Compounds , Structure-Activity Relationship , PleuromutilinsABSTRACT
Pleuromutilins were discovered as natural-product antibiotics in 1950. Tiamulin was the first pleuromutilin compound to be approved for veterinary use in 1979, followed by valnemulin in 1999. It was not until 2007 that retapamulin became the first pleuromutilin approved for use in humans. However, retapamulin is limited to topical application. Recent advances in lead optimization have led to the synthesis of pleuromutilins that combine potent antibacterial activity with favorable pharmaceutical properties, making these compounds suitable for oral and intravenous delivery. Most pleuromutilins have an antibacterial spectrum that spans the common pathogens involved in both skin and respiratory tract infections. Two new pleuromutilins, BC-3205 and BC-7013 (both Nabriva Therapeutics AG), have entered clinical trials. In this review, the key properties of pleuromutilin derivatives, designed primarily through modifications at the C(14) side chain, are presented, and the potential of these compounds in systemic therapy in humans is discussed.
Subject(s)
Anti-Bacterial Agents/pharmacology , Drug Design , Animals , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/history , Clinical Trials as Topic , Diterpenes/administration & dosage , Diterpenes/history , Diterpenes/pharmacology , History, 20th Century , History, 21st Century , Humans , Microbial Sensitivity Tests , Polycyclic Compounds , Respiratory Tract Infections/drug therapy , Respiratory Tract Infections/microbiology , Skin Diseases, Bacterial/drug therapy , Skin Diseases, Bacterial/microbiology , Structure-Activity Relationship , PleuromutilinsABSTRACT
Grayanotoxin is a naturally occurring sodium channel toxin which enters the human food supply by honey made from the pollen and nectar of the plant family Ericaceae in which rhododendron is a genus. Grayanotoxin/mad honey poisoning is a little known, but well studied, cholinergic toxidrome resulting in incapacitating and, sometimes, life-threatening bradycardia, hypotension, and altered mental status. Complete heart blocks occur in a significant fraction of patients. Asystole has been reported. Treatment with saline infusion and atropine alone is almost always successful. A pooled analysis of the dysrhythmias occurring in 69 patients from 11 different studies and reports is presented. The pathophysiology, signs, symptoms, clinical course, and treatment of grayanotoxin/mad honey poisoning are discussed. In the nineteenth century grayanotoxin/mad honey poisoning was reported in Europe and North America. Currently, documented poisoning from locally produced honey in Europe or North America would be reportable. Possible reasons for this epidemiologic change are discussed.